stockrowCorbus Pharmaceuticals Holdings, Inc.
CRBP Healthcare Biotechnology
- EPS
- −25.7%
- Free cash flow
- −78.5%
Quarter to June 2026, against a year earlier
Follow CRBP
Alert me
Corbus Pharmaceuticals Holdings, Inc. (CRBP) EV/Sales
As of 6 November 2026, Corbus Pharmaceuticals Holdings, Inc. (CRBP) trades at a EV/Sales of −23.8×. Over the past ten years it has ranged from −43.5× (March 2025) to 361× (August 2024); the current reading is higher than 2% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2021 | −1.8× | — |
| FY2020 | 7.8× | (13.96%) |
| FY2019 | 9.0× | (85.09%) |
| FY2018 | 60.4× | (56.16%) |
| FY2017 | 138× | (20.79%) |
| FY2016 | 174× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2021 | 26.1× | (44.06%) |
| Jun 2021 | 46.6× | 6.83% |
| Mar 2021 | 43.7× | 463.21% |
| Dec 2020 | 7.8× | (45.90%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CRBP Corbus Pharmaceuticals Holdings, Inc. | −23.8× |
| XBIT XBiotech Inc. compare | −10.5× |
| BOLD Boundless Bio, Inc. compare | n/m |
| TELO Telomir Pharmaceuticals, Inc. compare | n/m |
| XLO Xilio Therapeutics, Inc. compare | 0.5× |
| HRTX Heron Therapeutics, Inc. compare | 1.0× |
| GOSS Gossamer Bio, Inc. compare | 4.1× |
| RNXT RenovoRx, Inc. compare | 17.8× |
| CLNN Clene Inc. compare | 196× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)